Genentech's divarasib posts this win as KRAS-targeting therapies demonstrate ‘game-changing’ potential in hard-to-treat cancers. The post Roche’s KRAS blocker touts best-in-class NSCLC potential in Phase III trial appeared first on Clinical Trials Arena .